$NROM

NOBLE ROMANS INC (NROM): Submission of Matters to a Vote of Security Holders

NOBLE ROMANS INC (NROM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. Noble Roman’s, Inc. (the “Registrant”) held its 2026 Annual Meeting of Shareholders on September 15, 2026 (the “Annual Meeting”). As of the record date for the Annual Meeting, August 10, 2026, there were 22,707,749 sh

Original reporting
Published Sep 16, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NROM
Neutral
high confidence
Mentioned
$NROM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NROMNeutralLow
01

Why it matters

The filing provides the first public record of the board changes; impact on price is expected to be limited.

02

Market read

Routine corporate governance update with low trading relevance.

03

What to watch

Potential hidden agenda behind director appointments or auditor change could affect future disclosures.

Relevance 6/10Novelty 7/10Timing: post‑annual meeting filing

Background

Noble Romans Inc. filed a Form 8‑K detailing the outcomes of its 2026 annual shareholders meeting, including director elections and auditor ratification.

Company-level read

Ticker impact

$NROMNeutralHigh confidence
Context

SEC 8‑K reports election of two directors and ratification of the auditor at the 2026 annual meeting.

Expected impact

minimal, likely flat to slight uptick if investors view new directors positively.

Evidence & confidence

The filing is a routine corporate action with no material financial disclosure; market reaction is typically muted.

Market effects

None; the filing pertains only to Noble Romans Inc.

No regional effect expected.

Insignificant.

Counterpoint

If the newly elected directors signal a strategic shift, the stock could see a modest rally.

Key entities

  • Noble Romans Inc.

    Issuer of the 8‑K filing.

  • Stephano Slack, LLC

    Independent registered public accounting firm ratified for 2026.

Related articles

$NROMMed

Noble Romans, Inc.: Noble Roman's Announces Financial Data for the 6 Months ended June 30th and other Related Updates

Noble Roman’s, Inc. (OTCQB:NROM) reported 6-month ended June 30, 2026 revenue of about $8.0M vs $7.8M in 2025, and net income after tax accrual about $311k vs $329k. A $6.9M SOFR+4% loan from Lake Forest Bank & Trust replaced prior debt, creating a one-time $353k write-off. Same-store Craft Pizza & Pub sales fell 0.8%.

$CRWVHighAI 8/10

Why CoreWeave Is Tumbling Hard While the Market Is Soaring

CoreWeave (CRWV) shares fell 3.5% midday, underperforming the S&P 500's 0.9% rise, amid a $3.5B convertible note offering and 35M share ATM program, raising dilution concerns. The company has $72B in liabilities and a $626M Q2 net loss, despite strong demand and revenue growth. Analysts maintain an average $144 price target.

$QBTSHigh

QBTS Stock Rallies As U.S. Backs Quantum Expansion

D-Wave Quantum Inc. (QBTS) stock rose 7.87% on U.S. government backing and positive analyst coverage. The company secured up to $100M in CHIPS Act funding, and BMO Capital initiated coverage with a $35 price target. QBTS reported $24.6M annual revenue, negative margins, and $296.6M in cash. NTT DOCOMO's use of its quantum tech also drove interest.

$SNYLowAI 8/10

Sanofi announces new $925 million flu vaccine facility in Toronto

Sanofi announced a $925 million flu vaccine facility in Toronto, with partial funding from the federal government ($55 million) and the City of Toronto. The project is expected to create 300 jobs and enhance local vaccine supply. Premier Doug Ford emphasized Ontario's investment philosophy and the importance of domestic vaccine production.